Session Details
[P1]Poster Session Core Time (Odd no.)
Mon. Mar 2, 2026 6:30 PM - 7:30 PM JST
Mon. Mar 2, 2026 9:30 AM - 10:30 AM UTC
Mon. Mar 2, 2026 9:30 AM - 10:30 AM UTC
Poster Session (Ohwada Foyer)
[P1-1]In vitro induction of human germinal center B-cells
*David Geoffrey Priest1, Wataru Ise2,3, James B. Wing1,3,4 (1. Human Single Cell Immunology Team, Division of Microbiology and Immunology, Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, Japan (Japan), 2. Regulation of Host Defense Team, Division of Microbiology and Immunology, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan (Japan), 3. Center for Advanced Modalities and DDS (CAMaD), Osaka University, Osaka, Japan (Japan), 4. Laboratory of Human Single Cell Immunology, World Premier International Research Center Initiative Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Osaka, Japan (Japan))
[P1-3]Biphasic innate immune cell-mediated memory responses confer protection against viral infection
*Asuka Joy Tobuse1,2, Kouji Kobiyama1,3,4, Jun Tsuchida1, Teppei Hara1, Masamitsu N Asaka5, Daichi Utsumi5, Yaeko Nakajima-Takagi8, Mariana Silva Almeida7, Motohiko Oshima8, Tomoya Hayashi1,9,3, Burcu Temizoz1,9,3, Cevayir Coban7,9,3, Yasuhiro Yasutomi5,6, Atsushi Iwama8, Ken J Ishii1,3,9 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 2. Department of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo (Japan), 3. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (Japan), 4. Division of Rheumatology, Department of medicine, University of California San Diego, La Jolla, California (USA), 5. Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (Japan), 6. Institute for Vaccine Research and Development, Hokkaido University (Japan), 7. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 8. Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo (Japan), 9. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo (Japan))
[P1-5]Prime-Push Mtb Vaccination Drives Immuno-Switching in the Tumor Microenvironment
*Burcu Temizoz1,2,6,7, Nobuyoshi Kobayashi3,2, Yuta Ohira3,2, Areej S1, Kou Hioki1, Mai Onaga1, Tomoya Hayashi1,2,6,7, Michelle Sue Jann Lee5, Takayuki Horii3, Cevayir Coban5,4,7,6, Kouji Kobiyama1,6,8, Ken J. Ishii1,2,4,6,7 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan (Japan), 2. Center for Adjuvant and Vaccine Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8, Osaka, Japan (Japan), 3. Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1 Numagami, Oshikiri, Kumagaya-shi, Saitama, Japan (Japan), 4. WPI Immunology Frontier Research Center (IFReC), Osaka University, 3-3-1, Osaka, Japan (Japan), 5. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, 4-6-1, Tokyo, Japan (Japan), 6. International Vaccine Design Center (VDesC), The Institute of Medical Science (IMSUT), The University of Tokyo, 4-6-1, Tokyo, Japan (Japan), 7. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo 108-8639, Japan. (Japan), 8. Division of Rheumatology, Department of Medicine, University of California San Diego, La Jolla (USA))
[P1-7]Identification of the TCR-mTORC1-TET axis and epigenetic regulators that govern iTreg stability
*Akira Nakajima1, Tatsumasa Hasegawa1, Tomohide Kinoshita1, Toru Kobayashi1, Shohei Hori1 (1. Graduate School of Pharmaceutical Sciences, The University of Tokyo (Japan))
[P1-9]Single-cell analysis reveals age-related diferences in the T cell response to COVID-19 mRNA vaccines
*Ayana Sunami1,2, Norihide Jo1,3, Yoko Hamazaki1,2,4 (1. Center for iPS Cell Research and Application, Kyoto University (Japan), 2. Laboratory of Immunobiology, Graduate School of Medicine, Kyoto University (Japan), 3. Alliance Laboratory for Advanced Medical Research, Graduate School of Medicine, Kyoto University (Japan), 4. Kyoto University Immunomonitoring Center (Japan))
[P1-11]Design of a Universal mRNA T Cell Vaccine Against Multiple Genotypes of Crimean-Congo Haemorrhagic Fever Virus
*Takumi Kawasaki1, Moe Ikegawa1, Yasuteru Sakurai1, Jiro Yasuda1 (1. National Research Center for the Control and Preventation of Infectious Diseases Nagasaki University (Japan))
[P1-13]Independent germinal centers are induced in primary and secondary draining lymph nodes.
*Ryutaro Kotaki1,2,3, Yoshimasa Takahashi2, Takeshi Inoue1,3 (1. The UTOPIA Center, The University of Tokyo (Japan), 2. Research Center for Vaccine Development, NIID, JIHS (Japan), 3. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (Japan))
[P1-15]Transferrin Defines the Microenvironment of Tertiary Lymphoid Structures and Supports the Maintenance of Tissue-Resident Memory T Cells
*Takahisa Hishiya1, Kiyoshi Hirahara1 (1. Department of immunology, Chiba University (Japan))
[P1-17]Human Monoclonal Antibodies Capture Nuanced Antigenic Drift of the H3 Hemagglutines of Seasonal Influenza Viruses
*Calvin Duong1,4, Yui Honjo1, Mifumi Goto1, Jisuk Ko1, David Pattinson5, Lavanya Babujee5, Gabriele Neumann5, Seiya Yamayoshi2,3,4, Yoshihiro Kawaoka1,2,3,4,5 (1. Division of Virology, Institute of Medical Science, University of Tokyo, Japan (Japan), 2. International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo (Japan), 3. Research Center for Global Viral Infections, National Center for Global Health and Medicine Research Institute (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (Japan), 5. Department of Pathobiological Sciences, School of Veterinary Medicine (USA))
[P1-19]A Single-Cell Multi-Omics Approach Reveals Pathogenic Roles and Antigen Specificity of ZEB2-Driven ThA Cells in Systemic Lupus Erythematosus
*Hiroyuki Teruya1, Toshiyuki Ushijima1, Manaka Goto1,2, Hideyuki Takahashi1, Takahiro Itamiya1,2, Hirofumi Shoda3, Haruka Tsuchiya1, Mineto Ota1, Tomohisa Okamura1,2, Keishi Fujio1 (1. Department of Allergy and Rheumatology, Graduation School of Medicine, the University of Tokyo (Japan), 2. Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo (Japan), 3. Department of Rheumatology, Tokyo Medical University Hospital (Japan))
[P1-21]Reduced Antigen-Presenting Cell Function Associated with Lysosomal Dysfunction in Older Adults
*Mengqian Li1, Kohei Kometani1, Norihide Jo1, Yoko Hamazaki1 (1. Kyoto University Center for iPS Cell Research and Application (Japan))
[P1-23]STING involvement in immune responses to tick-borne encephalitis virus
*Moe Ikegawa1, Kentaro Yoshii2, Takumi Kawasaki1 (1. Resarch Unit of Immune Dynamics in Viral Infections ,National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University (Japan), 2. Research Unit of Viral Ecology, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University (Japan))
[P1-25]The role of TBK1 in B cells in the maintenance of chronic germinal centers in Peyer’s Patches at steady-state and during systemic infection
*Mariana Silva Almeida1,2,3, Hiroaki Matsumori1,2,3, Reiko Shinkura3,4, Takeshi Inoue5, Jun Kunisawa6, Ken J Ishii2,3,7, Cevayir Coban1,2,3 (1. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo (Japan), 2. International Vaccine Design Center, Institute of Medical Science (IMSUT), The University of Tokyo (Japan), 3. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo (Japan), 4. Laboratory of Immunology and Infection Control, Research Division for Quantitative Life Sciences (IQB), The University of Tokyo (Japan), 5. Department of Molecular Systems Immunology, The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA) (Japan), 6. Laboratory of Vaccine Materials and Laboratory of Gut Environmental System,Microbial Research Center for Health and Medicine,National Institutes of Biomedical Innovation,Health and Nutrition(NIBIOHN) (Japan), 7. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo (Japan))
[P1-27]Identification of a novel immune regulatory mechanism involving WDR11
*WEI JIE CHEAH1, Gabriel Talaia1,2, Tsutomu Tanaka1,2, Koichi Kobayashi1,2,3 (1. Hokkaido University Graduate School of Medicine (Japan), 2. Hokkaido University Institute for Vaccine Research and Development (IVRED) (Japan), 3. Texas A&M Health Science Center (USA))
[P1-29]A Screening Platform for Natural Products Modulating IgA Secretion Based on Human IgA-Producing Hybridoma Clones
*Yuqing WU1,2, Zhongwei ZHANG1,2, Tamami MATSUSHITA1,2, Takuya NAKAGAWA3, Toyoyuki HANAZAWA3, Mariko KITAJIMA4, Hayato ISHIKAWA4, Hiroshi KIYONO2,5,6,7, Yosuke KURASHIMA1,2,5,8 (1. Department of Innovative Medicine, Graduate School of Medicine, Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba University, Chiba (Japan), 2. Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba (Japan), 3. Department of Otorhinolaryngology, Head and Neck Surgery, Chiba University, Graduate School of Medicine, Chiba (Japan), 4. Laboratory of Natural Products and Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University (Japan), 5. Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (CU-UCSD cMAV), Department of Medicine, School of Medicine, San Diego, CA (USA), 6. Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba (Japan), 7. Division of Comparative Pathology and Medicine, Department of Pathology, University of California, San Diego, CA (USA), 8. Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba,University, Chiba (Japan))
[P1-31]Identification of Prognostic Biomarkers and Therapeutic Targets for Severe Respiratory Diseases using an Influenza Mouse Model
*Saya Kuribayashi1, Yuko Arita2, Toshinori Endo2, Yuichi Koshiishi3, Marumi Ohno3, Masashi Shingai3, Kiyoshi Takayama1 (1. NB health laboratory co. ltd (Japan), 2. Information Science and Technology, Hokkaido University (Japan), 3. International Institute for Zoonosis Control, Hokkaido University (Japan))
[P1-33]Presenting MHC II determines fidelity of SARS-CoV-2 spike peptide predicted binding
*Charles Schutt1, Deren Birol1, Xiuyuan Lu1, Sho Yamasaki1,2,3 (1. Immunology Frontier Research Center (IFReC), The University of Osaka (Japan), 2. Research Institute for Microbial Diseases (RIMD), The University of Osaka (Japan), 3. Center for Infectious Disease Education and Research (CiDER), The University of Osaka (Japan))
[P1-35]Study of cryopreservation solutions for maintaining the viability of malaria parasite sporozoites
*Hiroaki Matsumori1,2,3, Mariana Silva Almeida1,2,3, Cevayir Coban1,2,3 (1. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo (Japan) (Japan), 2. International Vaccine Design Center, Institute of Medical Science (IMSUT), University of Tokyo (Japan) (Japan), 3. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo (Japan) (Japan))
[P1-37]TLR7 Stress Response Disrupts Immune Privilege and Triggers
Submandibular Sialadenitis
*Takuma Shibata1, Kensuke Miyake2, Emi K Nishimura1 (1. Division of Aging and Regeneration, The Institute of Medical Science, The University of TOKYO (Japan), 2. Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University (Japan))
[P1-39]Mechanism of GC B cell differentiation into memory B cell
*Takeshi Inoue1 (1. The UTOPIA Center, The University of Tokyo (Japan))
[P1-41]Identification of commensal bacteria-derived molecules that are important for a subset of γδT cells
*Shunka Kano1, Ichita Hasegawa1, Yukihiro Endo1, Motoko Kimura1 (1. Graduate School of Medicine, Chiba University (Japan))
[P1-43]Uncovering genetic regulators of phagocytosis via large-scale CRISPR-Cas9 screens in human monocytic cells.
*Carlos le Sage1, Makoto Suematsu1 (1. Central Institute for Experimental Medicine and Life Science (Japan))
[P1-45]Development of a PEG Substitute Lipid for LNP Formulations to Reduce Immunogenic Risk Associated with Anti-PEG Antibodies
*Hirano Ayaka1, Matsumoto Makoto1, Mukai Hidefumi1, Kawakami Shigeru1 (1. Nagasaki University (Japan))
[P1-47]Recovery of Infectious Recombinant Human Norovirus Using Zebrafish Embryos
*Tomohiro Kotaki1, Yuki Akieda1, Zelin Chen1, Megumi Onishi1, Sayuri Komatsu1, Daisuke Motooka1, Hiroko Omori1, Shigeyuki Tamiya2, Yuta Kanai1, Shohei Minami1, Takahiro Kawagishi1,3, Naomi Sakon4, Shintaro Sato2, Tohru Ishitani1,5, Takeshi Kobayashi1,3,5 (1. Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. Wakayama Medical University (Japan), 3. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 4. Osaka Institute of Public Health (Japan), 5. Center for Infectious Disease Education and Research, The University of Osaka (Japan))
[P1-49]Genome-wide CRISPR-A screening reveals AXL, a novel host factor involved in SFTSV entry
*ZECHENG JIN1,2,3, Shuhei Taguwa1,2,3, Junki Hirano2,3, Kentaro Uemura1,2,3, Chikako Ono1,2,3, Akatsuki Saito4, Tamaki Okabayashi4, Yusuke Maeda3, Taroh Kinoshita3,2, Yoshiharu Matsuura1,3,2 (1. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 2. Center for Infectious Disease Education and Research (CiDER) (Japan), 3. Research Institute for Microbial Diseases (RIMD) (Japan), 4. Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki (Japan))
[P1-51]Determining the host tropism of novel coronaviruses using AI protein structure predictions
Jarel Elgin Tolentino1, Victoria A. Jefferson2, Nicholas J. Catanzaro3, Ralph S. Baric3, Michael Letko2, *Spyros Lytras1, Kei Sato1 (1. The Institute of Medical Science, The University of Tokyo (Japan), 2. Paul G. Allen School for Global Health, Washington State University (USA), 3. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill (USA))
[P1-53]An mRNA-LNP vaccine induces cross-protective immunity against emerging H5N1 influenza viruses in mice
*Shintaro Shichinohe1, Qingxin Li1, Hiroki Tanaka2,3, Jessica Anindita3, Sara Yoshimoto1, Kaewaroon Nantaporn1,4, Makoto Shimooka1, Itsuki Anzai1, Hidetaka Akita2,3, Tokiko Watanabe1,2,5 (1. Department of Molecular Virology, Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 3. Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University (Japan), 4. The National Vaccine Institute (Thailand), 5. Center for Infectious Disease Education and Research (CiDER), The University of Osaka (Japan))
[P1-55]Identification and application of the packaging signals using reverse genetics for rotavirus
*Shohei Minami1, Yuta Kanai1, Hiroto Aoyama1, Kanako Matsumura1, Katsuhisa Hirai1, Sayuri Komatsu1, XueYing Li1, Zelin Chen1, Shizuka Sonoda1, Takahiro Kawagishi1,2, Tomohiro Kotaki1, Takeshi Kobayashi1,2,3 (1. Department of Virology, Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 3. Center for Infectious Disease Education and Research, The University of Osaka (Japan))
[P1-57]Mechanistic Analysis of Broadly Neutralizing Antibodies Against Diverse SARS-CoV-2 Variants
*Mizuki Yamamoto1, Yoko Hirayama1, Jun-ichiro Inoue2, Yasushi Kawaguchi1,3, Xuenan Xuan1 (1. Research Center for Asian Infectious Diseases, The Institute of Medical Science, The University of Tokyo (Japan), 2. The University of Tokyo Pandemic preparedness, Infection and Advanced research center (UTOPIA), The University of Tokyo (Japan), 3. Division of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan))
[P1-59]Isolation of Lassa virus glycoprotein variants resistant to a neutralizing antibody using a conditionally replicating glycoprotein-encoding retroviral vector in BSL2
*Yoshinao Kubo1, Manya Bakatumana Hans1, Hironori Sato2, Osamu Kotani2 (1. Institute of Tropical Medicine, Nagasaki University (Japan), 2. National Institute of Infectious Diseases (Japan))
[P1-61]Identification of viral determinants underlying differences in the multiplication of Chikungunya and O'nyong-nyong viruses in mosquito vector cells using a rapid reverse genetics system
*Ryotaro Nouda1,2, Masaharu Iwasaki1,2,3,4 (1. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 2. Research Institute for Microbial Diseases, The University of Osaka (Japan), 3. Center for Infectious Disease Education and Research, The University of Osaka (Japan), 4. RNA Frontier Science Division, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka (Japan))
[P1-63]Establishment of a lethal mouse model for Oz virus infection and its application for antiviral drug and vaccine evaluation
*Rio Harada1,2, Cassia Sousa Moraes1,2, Atsuko Inoue1,3, Chilekwa Kabamba1,2, Joshua Kranrod1,4, Shuichi Osawa5, Motohito Goto6, Koshiro Tabata1, Shinji Saito1, Gabriel Gonzalez 1, Noriko Nagata5, Mamoru Ito6, Makoto Suematsu6, Hideki Hasegawa1,7, Hirofumi Sawa1,8,9, Yukari Itakura1 (1. Institute for Vaccine Research and Development, Hokkaido University (Japan), 2. Graduate School of Infectious Diseases, Hokkaido University (Japan), 3. Faculty of Pharmaceutical Science, Graduate School of Life Science, Hokkaido University (Japan), 4. Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University (Japan), 5. Ibaraki Prefectural Institute of Public Health (Japan), 6. Central Institute for Experimental Medicine and Life Science (Japan), 7. National Institute of Infectious Diseases, Japan Institute for Health Security (Japan), 8. International Institute for Zoonosis Control, Hokkaido University (Japan), 9. One Health Research Center, Hokkaido University (Japan))
[P1-65]Development of a High-Throughput Neutralization Assay for Orthoflaviviruses
*Kaito Maeda1, Atsuko Inoue1,2, Chinatsu Nakamura1, Yukari Itakura1, Shinji Saito1, Hirofumi Sawa1,3,4, Koshiro Tabata1 (1. Institute for Vaccine Research and Development, The University of Hokkaido (Japan), 2. Faculty of Pharmaceutical Science, Graduate School of Life Science, Hokkaido University (Japan), 3. International Institute for Zoonosis Control, Hokkaido University (Japan), 4. One Health Research Center, Hokkaido University (Japan))
[P1-67]Paramyxovirus-based Platforms for the Development of Henipavirus Vaccines
*Yuying WANG1, Taishi Onodera2, Yuki Kitai1, Yukiko Akahori1, Hekai Yang1, Hiroshi Katoh1, Akihide Ryo2, Katsumi Maenaka3, Takao Hashiguchi4, Junki Maruyama5, Yoshimasa Takahashi2, Makoto Takeda1 (1. The University of Tokyo (Japan), 2. Japan Institute for Health Security, National Institute of Infectious Diseases (Japan), 3. Hokkaido University (Japan), 4. Kyoto University (Japan), 5. University of Texas Medical Branch (USA))
[P1-69]Generating leukemia-directed T cell immunity by using allogeneic iPS cell-derived invariant NKT cells
*Takahiro Aoki1 (1. Department of Medical Immunology, Chiba University (Japan))
[P1-71]Efficacy of an attenuated vaccinia virus DIs against mpox in the mouse model
*Kenichi Otaki1, Fumihiro Yasui2, Hirohito Ishigaki1, Naoko Kitagawa1, Michinori Kohara2, Koji Ishii3, Yasushi Itoh1 (1. Division of Pathogenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science (Japan), 2. Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science (Japan), 3. Department of Quality Assurance and Radiological Protection, National Institute of Infectious Diseases (Japan))
[P1-73]Reciprocal roles of interleukin-33 in a lipid nanoparticle mRNA vaccine-induced cytotoxic T cell and type 2 responses
*Kaiwen Liu1,2,3, Kouji Kobiyama1,2,3,8, Naoko Satoh-Takayama4, Tomoya Hayashi1,2,3, Burcu Temizoz1,2,3, Hideo Negishi1,2,3,5, Asuka Joy Tobuse1, Mai Onaga1, Peter D Katsikis6, Cevayir Coban2,3,7, Ken J Ishii1,2,3 (1. Division of Vaccine Science, IMSUT (Japan), 2. International Vaccine Design Center, IMSUT (Japan), 3. The UTOPIA Center, The University of Tokyo (Japan), 4. Precision Immune Regulation RIKEN ECL Research Unit, RIKEN Center for Integrative Medical Sciences (Japan), 5. Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, the University of Tokyo (Japan), 6. Department of Immunology, Erasmus University Medical Center (Netherlands), 7. Division of Malaria Immunology, the Institute of Medical Science, IMSUT (Japan), 8. Division of Rheumatology, Department of Medicine, University of California San Diego (USA))
[P1-75]Mechanistic dissection of IVReD vaccine candidate-induced protection against tuberculosis
*Shunsuke Sakai1, Satoru Mizuno1, Kazuhiro Matsuo1, Yasuhiro Yasutomi1,2 (1. IVReD, Hokkaido University (Japan), 2. Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (Japan))
[P1-77]Analysis of signaling pathways that induce mRNA vaccine-induced IL-6 production
*Yuji Kubota1, Takekawa Mutsuhiro1 (1. Division of Cell Signaling and Molecular Medicine, Institute of Medical Science, The University of Tokyo (Japan))
[P1-79]Investigation of the protection against tuberculosis by adjuvant-containing live-attenuated AIDS virus
*Yoshiaki Shibukawa1,2, Natsuko Yamakawa1, Emiko Urano1, Yasuhiro Yasutomi1 (1. Tsukuba primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (Japan), 2. Osaka university (Japan))
[P1-81]Innovative mucosal adjuvant development using heat-killed Escherichia coli
*Peng Gao1, Reiko Shinkura1 (1. Institute for Quantitative Biosciences, The University of Tokyo (Japan))
[P1-83]Development of cCHP nanogel based nasal vaccine for RSV infection.
*Yohei Uchida1, Shingo Umemoto1,2, Rika Nakahashi1,3, Hiroshi Kiyono1,3,4,5,6,7 (1. Department of Human Mucosal Vaccinology, Chiba University Hospital (Japan), 2. Department of Otorhinolaryngology and Head & Neck Surgery, Faculty of Medicine, Oita University (Japan), 3. Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University (Japan), 4. Future Medicine Education and Research Organization, Chiba University (Japan), 5. Department of Medicine, UC San Diego School of Medicine (USA), 6. CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV), UC San Diego School of Medicine (USA), 7. Division of Infectious Disease Vaccine R&D, Research Institute of Disaster Medicine, Chiba University (Japan))
[P1-85]Studies on Vaccines Against Dengue virus Infections
*Koshiro Tabata1, Takeshi Kurosu2, Masahiro Nakano2, Yukari Itakura1, Gabriel Gonzalez1, Shinji Saito1, Tadaki Suzuki2, Hirofumi Sawa1 (1. IVReD, Hokkaido University (Japan), 2. NIID, Japan Institute for Health Security (Japan))
[P1-87]Development of an Evaluation Platform for Respiratory Mucosal Vaccines Using Primary Human Airway Epithelial Models
*Misako Nakayama1, Tomoya Hayashi1, Burcu Temizoz1, Hideo Negishi1, Noritake Kikunishi2, Tetsukan Woo2, Ken J Ishii1 (1. Institute of Medical Science, Department of Infection and Microbiology, Division of Vaccine Science (Japan), 2. Department of General Thoracic Surgery, Yokohama City University Medical Center Hospital, Yokohama (Japan))
[P1-89]Validation of AI-predicted Dengue virus-specific HLA class I epitopes for vaccine development
*Shara Bakytbek1,2,3, Farzaneh Valanezhad1,2,3, Ayako Hyuga1,2,3, Shin-Ichi Inoue2,4, Yui Katsuyuki5, Shusaku Mizukami3,6, Risa Nakamura1,2,3, Haruka Abe7, Futoshi Hasebe2,7, Kazuhide Onoguchi8, Sebastian Kapell9,10, Kouichi Morita3,11, Shinjiro Hamano1,2,3 (1. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki (Japan), 2. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki (Japan), 3. The Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University, Nagasaki (Japan), 4. Department of Molecular Microbiology and Immunology, Division of Immunology, Nagasaki University, Nagasaki (Japan), 5. SHIONOGI Global Infectious Diseases Division Institute of Tropical Medicine, Nagasaki University, Nagasaki (Japan), 6. Department of Immune Regulations, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 7. Vietnam Research Station, center for Infectious Disease Research in Asia and Africa, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 8. AI Drug Development Division, NEC Corporation, Tokyo (Japan), 9. Department of Vaccine Informatics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 10. NEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo (Norway), 11. Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan))
[P1-91]Multi-modal integration of genome, transcriptome, and epigenome in resting and stimulated CD4 T cells reveals a dynamic landscape of immune-mediated disease genetics.
*Saya Hisano1,3, Akari Suzuki1, Akiko Oguchi1,4, Rintaro Fujimoto1,2,3, Hiroki Kitaoka1,2, Raku Son1,4, Ryuya Edahiro1,3, Go Sato1,2, Yoshihiko Tomofuji1,2, Yasuhiro Murakawa1,4, Yukinori Okada1,2,3, Kazuhiko Yamamoto1 (1. RIKEN Center for Integrative Medical Sciences (Japan), 2. The University of Tokyo (Japan), 3. The University of Osaka (Japan), 4. Kyoto University (Japan))
[P1-93]Dissecting cross-population polygenic heterogeneity of multimorbidity across respiratory and cardiometabolic diseases
*Yuji Yamamoto1,2, Yuya Shirai1,2,3,4, Kyuto Sonehara1,4,5, Shinichi Namba1,4,5, Takafumi Ojima1,4,5,6, Kenichi Yamamoto1,7, Ryuya Edahiro1,2,4, Ken Suzuki1,8, Akinori Kanai9, Yoshiya Oda10, Yutaka Suzuki9, Takayuki Morisaki11, Akira Narita6, Yoshito Takeda2, Gen Tamiya6, Masayuki Yamamoto6, Koichi Matsuda11, Atsushi Kumanogoh2, Toshimasa Yamauchi8, Takashi Kadowaki8,12, Yukinori Okada1,3,4,5 (1. Department of Statistical Genetics, Graduate School of Medicine, The University of Osaka (Japan), 2. Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka (Japan), 3. Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), The University of Osaka (Japan), 4. Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences (Japan), 5. Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo (Japan), 6. Tohoku Medical Megabank Organization, Tohoku University (Japan), 7. Department of Pediatrics, Graduate School of Medicine, The University of Osaka (Japan), 8. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo (Japan), 9. Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo (Japan), 10. Department of Lipidomics, Graduate School of Medicine, The University of Tokyo (Japan), 11. Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo (Japan), 12. Toranomon Hospital (Japan))
[P1-95]Multi-layered single-cell genomics deconvolutes biological mechanisms underlying clonal hematopoiesis and mitochondrial heteroplasmy in infectious and autoimmune diseases
*Ryuya Edahiro1,2, Go Sato1,2,3, Yuya Shirai1,2, Ryunosuke Saiki4, Shuhei Sakakibara1, Seishi Ogawa4, Atsushi Kumanogoh1, Yukinori Okada1,2,3 (1. Graduate School of Medicine, The University of Osaka (Japan), 2. RIKEN Center for Integrative Medical Sciences (Japan), 3. Graduate School of Medicine, The University of Tokyo (Japan), 4. Kyoto University (Japan))
[P1-97]Uncovering human immunity through multilayer omics integration of immune cells
*Rintaro Fujimoto1,2,3, Hiroki Kitaoka1,2, Saya Hisano1,3, Ryuya Edahiro1,3, Go Sato1,2,3, Yoshihiko Tomofuji1,2, Akari Suzuki1, Yukinori Okada1,2,3, Kazuhiko Yamamoto1 (1. RIKEN Center for Integrative Medical Sciences (Japan), 2. The University of Tokyo (Japan), 3. The University of Osaka (Japan))
[P1-99]A cross-population compendium of gene–environment interactions uncovers the dynamics of genetic architecture
*Shinichi Namba1,2,3, Kyuto Sonehara1,2,3, Yuriko N Koyanagi4, Takezo Kikuchi1, Takafumi Ojima2,3,5, Ryuya Edahiro2,3, Go Sato1,2,3, Taiki Yamaji6, Hiroyuki Ueda2, Kenichi Yamamoto2, Akinori Kanai1, Shinichi Higashiue7, Shuzo Kobayashi7, Hiroki Yamaguchi8, Yasunobu Nagata8, Yasushi Okazaki9, Naoyuki Matsumoto9, Kenta Motomura10, Hidenobu Koga10, Asahi Hishida11, Hiroaki Ikezaki12, Megumi Hara13, Mako Nagayoshi14, Isao Oze4, Shiori Nakano6, Yoshiya Oda1, Yutaka Suzuki1, Motoki Iwasaki6, Norie Sawada6, Keitaro Matsuo4, Takayuki Morisaki1, Toshimasa Yamauchi1, Takashi Kadowaki15, Koichi Matsuda1, Yukinori Okada1,2,3 (1. The University of Tokyo (Japan), 2. The University of Osaka (Japan), 3. RIKEN Center for Integrative Medical Sciences (Japan), 4. Aichi Cancer Center (Japan), 5. Tohoku University (Japan), 6. National Cancer Center (Japan), 7. Tokushukai Group (Japan), 8. Nippon Medical School (Japan), 9. Juntendo University (Japan), 10. Iizuka Hospital (Japan), 11. Aichi Medical University (Japan), 12. Kyushu University (Japan), 13. Saga University (Japan), 14. Nagoya University (Japan), 15. Toranomon Hospital (Japan))
[P1-101]Vaccines and novel therapeutic modalities for cardiovascular diseases
*Seitaro Nomura1 (1. The University of Tokyo Hospital (Japan))
[P1-103]Generating Mouse Models to Study OSKM Reprogramming and Immune Cell Epigenetics
*Sho Ohta1, Yasuhiro Yamada1 (1. Graduate School of Medicine, The University of Tokyo (Japan))
[P1-105]ADPKD Cynomolgus Monkey Models for Comorbidity Research in Viral Infection and Vaccine Studies
*Masatsugu Ema1, Toshifumi Morimura1, Yasushi Itoh2, Shoma Matsumoto1 (1. RCALS, Shiga University of Medical Science (Japan), 2. Dept. of Pathology (Japan))
[P1-107]Utilization of Humanized Liver Mice in Drug Discovery Research
*Hiroshi Suemizu1, Yuichiro Higuchi1, Shotaro Uehara1, Nao Yoneda1, Kazutoshi Murai2, Masao Honda2 (1. Central Institute for Experimental Medicine and Life Science (Japan), 2. Kanazawa University Graduate School of Medical Science (Japan))
[P1-109]Monkey-tropic HIV-1 derivated virus induce CD4 T cell decline in Cynomolgus macaques
*Maya Shofa1, Emiko Urano1, Akatsuki Saito2, Yasuhiro Yasutomi1 (1. Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) (Japan), 2. Department of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, Miyazaki, Miyazaki (Japan))
[P1-111]Pandemic Vaccine Development Contingency Planning (PVDCP)
*JUNETSU IGARASHI1, Kimiyo Kamamoto-Shono1, Yoshihiro Takashima1, Takayuki Yoshioka1 (1. CAMaD, The University of Osaka (Japan))
[P1-113]Epithelial stem cells drive non-immune antiviral defense in stratified epithelia
*JINJUE LIANG1, Takuma Shibata1, Emi Nishimura1, Kosuke Takeshima2, Yasushi Kawaguchi2 (1. Division of aging and regeneration,The University of Tokyo (Japan), 2. Division of Molecular Virology,The University of Tokyo (Japan))
[P1-115]New High-Efficiency Aseptic Filling System for Investigational Drugs developed by UTOPIA
-Contributing to the Early Transition from Basic Research to Clinical Development-
*Katsuhiko Horibe1 (1. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (Japan))
[P1-117]Population-scale lipidomics of human immune cell subsets reveals lipid signatures associated with activation, sex, age, and individual variability
*Yosuke Isobe1, Hiroshi Tsugawa1, Makoto Arita1 (1. RIKEN Center for Integrative Medical Sciences (Japan))
[P1-119]Good Practices in Science Communication and Media Relations –Connecting Science and Society-
*Yuji Watanabe1, Hideki Toya2, Yuka Masshardt3, Yuriko Kano4, Hiroshi Mizuuchi1 (1. Chiba University, Synergy Institute for Futuristic Mucosal Vaccine Research and Development (Japan), 2. Public Relations Office, Chiba University (Japan), 3. Academic Research & Innovation Management Organization, Chiba University (Japan), 4. Chiba University Hospital (Japan))
[P1-121]Cryo-electron tomography of Influenza virus
*Shunsuke Kita1, Souta Kobayashi1, Toshiki Sekiya1, Naoki Nomura1, Chimuka Handabile1, Shingai Masashi1, Hiroshi Kida1, Katsumi Maenaka1 (1. IVReD, Hokkaido University (Japan))
[P1-123]BSL3 Cryo-ET-guided design of SARS-CoV-2 vaccines
*Katsumi Maenaka1 (1. Faculty of Pharamaceutical Siences, Hokkaido University (Japan))
[P1-125]ViroChart: Inferring Viral Properties from Host Gene Expression Signatures
*Junna Kawasaki1,2,3, Jumpei Ito4,5, Michiaki Hamada2, Tadaki Suzuki1,3 (1. Department of Infectious Disease Pathobiology, Graduate School of Medicine, Chiba University (Japan), 2. Faculty of Science and Engineering, Waseda University, Tokyo (Japan), 3. Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo (Japan), 4. Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 5. International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo (Japan))
[P1-127]A web-based platform for exploring integrated multi-omics data from the human immune reference dataset
Jessica Severin1, Shohei Asami1, Hiroaki Hatano1, Tamotsu Kato1, Takahiro Nishino1, Koshi Imami1, Kazuyoshi Ishigaki1, Yukinori Okada1, Akari Suzuki1, Kazuhiko Yamamoto1, *Takeya Kasukawa1 (1. RIKEN Center for Integrative Medical Sciences (Japan))
[P1-129]Development of IL-12-expressing HSV-1 for malignant melanoma
*Hitomi Nakamura1, Miwako Iwai1, Tomoki Todo1 (1. Division of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo (Japan))
[P1-131]Development of a Non-Invasive Screening Method for Anal HSIL and Anal Cancer Using Fecal and Anal Swab Detection of HPV16/18 E6/E7 Antigens
*Yoshiaki Kanno1, Aya Ishizaka1, Iwao Kukimoto2, Michiko Koga1,3 (1. Division of Infectious Diseases, Advanced Clinical Research Center, the Institute of Medical Science, The University of Tokyo (Japan), 2. Center for Pathogen Genomics, Japan Institute for Health Security (Japan), 3. The UTOPIA Center, The University of Tokyo (Japan))
[P1-133]Evaluation of the Relationship Between Antibody Responses and Viral Shedding in Bovine Coronavirus–Infected Cattle
*Wataru Sekine1, Natsuki Otani2, Hiroho Ishida3, Erika Hujimoto2, Yuji Nakamura2, Kosuke Ohira1, Kaixin Li1, Misa Katayama1, Ayano Ichikawa1, Yuta Wakabayashi1, Akiko Uema1, Tadaki Suzuki4, Shin Murakami1, Sho Miyamoto4, Taisuke Horimoto1 (1. Department of Veterinary Medical Science, The University of Tokyo (Japan), 2. Chiba Prefectural Agricultural Mutual Aid Association (Japan), 3. Laboratory of Infectious Diseases, Azabu University (Japan), 4. Laboratory of Infectious Disease Pathobiology, Chiba University (Japan))
[P1-135]Immune Evasion by Plasmodium falciparum: RIFIN-mediated Suppression of NK cell Cytotoxicity via LILRB1 domain3
Rina Sakuno1, *Farahana Kresno Dewayanti1, Tsubasa Nishi1, Shiroh Iwanaga1 (1. The University of Osaka (Japan))
[P1-137]Development of a blood-stage vaccine for Plasmodium falciparum malaria
Shinya Miyazaki1,2, Akiko Baba1,2, Vegard Børve Sørdal3, Huai Chuang1,2, Lluis Artus Suarez3, Matheus Ferraz3, Ioannis Vardaxis3, Agnieszka Gromadka3, Shusaku Mizukami1,4, Sebastian Kapell1,5, Kaidre Bendjama3, Kazuhide Onoguchi6, *Osamu Kaneko1,2 (1. Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance, Nagasaki Univ. (Japan), 2. Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 3. NEC Oncoimmunity AS (Norway), 4. Department of Immune Regulation, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 5. Department of Vaccine Informatics, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 6. NEC Corporation (Japan))
[P1-139]De Novo Design of Protein Antigens Mimicking the Hydrophobic Groove Epitope in Influenza HA Stem
*Ryo Matsunaga1, Tomomi Aoki1, Kouhei Tsumoto1,2 (1. School of Engineering, The University of Tokyo (Japan), 2. Institute of Medical Science, the University of Tokyo (Japan))
[P1-141]Citizens’ attitudes toward vaccination in the next pandemic and strategies to improve acceptance
Masakaze Hamada1, Junna Kawasaki2, Naoko Fujita1, Ryo Komorizono1, Mie Kobayashi-Ishihara1, Takahiro Tabuchi3, *Yuki Furuse1 (1. UTOPIA, University of Tokyo (Japan), 2. cSIMVa, Chiba University (Japan), 3. Tohoku University (Japan))
[P1-143]Development of a Platform Technology Enabling Diverse Chemical Modifications in mRNA Synthesis
*Koji Hashimoto1 (1. Graduate School of Arts and Sciences, The University of Tokyo (Japan))
[P1-145]Regulation of Inflammation-related Myeloid Cell Death by Polycomb Repressive Complex 1.1
*Yaeko Nakajima -Takagi1, Takanori Fukuta1, Atsushi Iwama1 (1. Institute of Medical Science, The University of Tokyo (Japan))
[P1-147]A Conserved Mechanism of Collision-Dependent mRNA Decay Mediated by Parallel Actions of GIGYF2 and ZNF598
*Satoshi Hashimoto1, Jennifer SAUERLAND2, Jiahuan ZENG1, Chisato Kikuguchi1, Toshifumi INADA1 (1. Division of RNA and Gene Regulation The Institute of Medical Science, The University of Tokyo (Japan), 2. University of Munich LMU (Germany))
[P1-149]Development and Applications of red Light-activated Transcription Factor
*Saki Inai1, Shinji C. Nagasaki2, Tomonori D. Fukuda1, Ikumi Nagano1, Mayumi Yamada4, Itaru Imayoshi1,2,3 (1. Laboratory of Brain Development and Regeneration, Division of Systemic Life Science, Kyoto University Graduate School of Biostudies (Japan), 2. Center for Living Systems Information Science, Kyoto University Graduate School of Biostudies (Japan), 3. Laboratory of Deconstruction of Stem Cells, Institute for Life and Medical Sciences, Kyoto University (Japan), 4. Laboratory of Cell Biology, Institute for Life and Medical Sciences, Kyoto University (Japan))
[P1-151]Antigen selection for vaccine development against invasive non-typhoidal Salmonella infection.
*Sarunporn Tandhavanant1,2, Hirotaka Hiyoshi1, Toshio Kodama1 (1. Department of Bacteriology, Institute of Tropical Medicine, Nagasaki University (Japan), 2. Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University (Thailand))